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Abstract Subarachnoid hemorrhage (SAH) can lead to dis-
abling motor, cognitive, and neuropsychological abnormal-
ities. Part of the secondary injury to cerebral tissues
associated with SAH is attributable to the neuroinflamma-
tory response induced by blood. Heparin is a pleiotropic
compound that reduces inflammatory responses in condi-
tions outside the central nervous system. Using a model of
SAH devoid of global insult, we evaluated the effect of
delayed intravenous (IV) infusion of heparin, at a dose that
does not produce therapeutic anticoagulation, on neuroin-
flammation, myelin preservation, and apoptosis. Adult male
rats underwent bilateral stereotactic injections of autologous
blood (50 μL) into the subarachnoid space of the entorhinal
cortex. The rats were implanted with mini-osmotic pumps
that delivered either vehicle or unfractionated heparin
(10 U/kg/h IV) beginning 12 h after SAH. No mechanical or
hemorrhagic injury was observed in the hippocampus. In
vehicle controls assessed at 48 h, SAH was associated with
robust neuroinflammation in the adjacent cortex [neutrophils,
activated phagocytic microglia, nuclear factor-kappa B, tumor
necrosis factor-alpha, and interleukin-1beta] and neurodegen-
eration (Fluoro-Jade C staining and loss of NeuN). In the
hippocampus, a muted neuroinflammatory response was indi-
cated by Iba1-positive, ED1-negative microglia exhibiting an
activated morphology. The perforant pathway showed Fluoro-
Jade C staining and demyelination, and granule cells of the
dentate gyrus had pyknotic nuclei, labeled with Fluoro-Jade C
and showed upregulation of cleaved caspase-3, consistent
with transsynaptic apoptosis. Administration of heparin sig-
nificantly reduced neuroinflammation, demyelination, and
transsynaptic apoptosis. We conclude that delayed IV infusion
of low-dose unfractionated heparin may attenuate adverse
neuroinflammatory effects of SAH.
Keywords Subarachnoid hemorrhage .
Neuroinflammation . Microglia . Heparin . Transsynaptic
apoptosis . Rat
Introduction
Subarachnoid hemorrhage (SAH) comprises 5–7 % of all
strokes [30, 38]. Acutely, 30 % or more of patients die from
the initial hemorrhage or rehemorrhage [30, 38]. Patients
who survive are at high risk for potentially severe neurolog-
ical and neuropsychological complications that develop dur-
ing the subsequent days and weeks, with well over half
succumbing to cerebral vasospasm, stroke, hydrocephalus,
or cognitive and neuropsychological deficits. Among the
worst cases are those in which the hemorrhage involves
the eloquent cortex, a situation frequently encountered with
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rupture of middle cerebral artery aneurysms [55, 56]. How-
ever, even among patients with mild hemorrhages (World
Federation of Neurosurgical Societies grade 1) who do not
suffer clinical or radiological vasospasm and who do not
experience perioperative complications, long-term psycho-
social and cognitive difficulties are still very common [6, 10].
Collectively, the various neurological and neuropsycho-
logical abnormalities brought on by SAH may be referred to
as “delayed neurological deficits” (DNDs) [74]. Historical-
ly, the most devastating cause of DNDs was considered to
be vasospasm leading to ischemia and stroke. Recently, a
large clinical trial demonstrated that successful prevention
of angiographic vasospasm by inhibition of endothelin sig-
naling does not translate into improved clinical outcomes
[48]. This landmark finding indicates that other mechanisms
of secondary injury induced by blood, possibly unrelated to
ischemia, play a crucial role in the development of DNDs [5,
8, 21, 31].
SAH has long been known to induce an inflammatory
response in blood vessels and neuronal tissues [11, 17, 24,
29, 52, 61, 64, 72, 73, 77, 78, 84]. Blood incites a robust
inflammatory response in the central nervous system that is
attributable, in part, to oxidative stress [43]. Many conven-
tional markers of inflammation are activated or upregulated
by SAH, including leukocytes, microglia, immune com-
plexes, complement, C-reactive protein, and numerous cyto-
kines and chemokines [11, 22, 24, 37, 62, 73, 77]. Despite
convincing evidence for the involvement of inflammation,
block of conventional inflammatory/immune pathways us-
ing a variety of agents (glucocorticoids, lazaroids, iron che-
lators, cyclosporine, tacrolimus, and nonsteroidal anti-
inflammatory drugs) has been of limited benefit in amelio-
rating DNDs associated with SAH, both in animal models
and in humans [11, 72]. Nevertheless, recent studies exam-
ining nonconventional anti-inflammatory agents have
shown promise [73, 77].
Heparin is a member of a family of polyanionic poly-
saccharides called glycosaminoglycans, composed of hex-
uronic acid and D-glucosamine residues joined by glycosidic
linkages [9]. Although clinically utilized almost exclusively
as an anticoagulant, heparin binding can interrupt numerous
biological pathways [45]. Heparin is a pleiotropic drug that
has long been recognized to have broad anti-inflammatory
and immunomodulatory activities that are independent of its
anticoagulant effect [18, 44, 45, 65, 80, 86]. On the exten-
sive list of heparin-binding proteins are several important
cytokines and all chemokines [18, 80, 86].
We recently reviewed the potential benefits of heparin as
a pleiotropic, prophylactic agent in the context of SAH,
showing how heparin can potentially antagonize most of
the pathophysiological mechanisms known to be activated
following SAH [74]. Here, we evaluated the effect of
delayed intravenous (IV) infusion of heparin, at a dose that
does not produce therapeutic anticoagulation [4, 42], in a
model of SAH involving the entorhinal cortex, the part of
the temporal lobe that projects directly to the hippocampus
via the perforant pathway. In this model, SAH was associ-
ated with robust neuroinflammation in the adjacent cortex
and white matter, with muted neuroinflammation in the
hippocampus, with demyelination of the perforant pathway,
and with transsynaptic apoptosis in the dentate gyrus. Here,
we report that delayed IV infusion of low-dose heparin
significantly reduced neuroinflammation, demyelination,
and transsynaptic apoptosis.
Methods
Subjects and Experimental Series
All experimental procedures were approved by the Univer-
sity of Maryland Institutional Animal Care and Use Com-
mittee. Male Wistar rats (300–350 g; Harlan, Indianapolis,
IN, USA) were used in this study, which was comprised of
two experimental series: In series 1, eight rats underwent
bilateral SAH (see below), three rats underwent unilateral
SAH (right side only), and three rats underwent sham injury
[same procedure but with injection of normal saline (NS)
instead of blood]. They were euthanized at 48 h. These
brains were used for pathological and histochemical charac-
terization of the model, including assessment for infarction
using 2,3,5-triphenyltetrazolium chloride (TTC) staining
(three rats with bilateral SAH), assessment of tissue damage
(Fluoro-Jade C staining) with saline vs. blood (three rats
each with unilateral saline vs. blood), and evaluation of the
hemorrhage location with hematoxylin and eosin (H&E)
staining (five rats with bilateral SAH). In series 2, 16 rats
underwent bilateral SAH and were implanted with mini-
osmotic pumps that delivered either NS (8 rats) or heparin
(8 rats; see below). These brains were used for further
histochemical and immunohistochemical characterization
of the model and to assess the effect of heparin treatment.
In accordance with “good laboratory practice,” surgical pro-
cedures were conducted by investigators blinded to treatment.
Rat Model of SAH
Anesthetized (ketamine 60 mg/kg and xylazine 7.5 mg/kg
intraperitoneally) rats spontaneously breathed room air sup-
plemented with oxygen to maintain 90 %<sO2<98 % by
pulse oximetry. Temperature was maintained at 37°C
using a heating pad regulated by a rectal temperature sensor
(Harvard Apparatus, Holliston, MA, USA). Surgical proce-
dures were carried out using aseptic techniques.
SAH was produced by injecting 50 μL of autologous
blood under stereotactic guidance into the subarachnoid
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space of the entorhinal cortex, bilaterally. First, the tail
artery was cannulated (PE-20 tubing) under microscopic
visualization. The head was fixed in a stereotaxic apparatus
(Stoelting Co., Wood Dale, IL, USA) and a midline scalp
incision was made. One burr hole was placed at (bregma and
midline as reference points) anterior–posterior, −7.7 mm;
lateral, +5 mm; a second burr hole was placed at anterior–
posterior, −7.7 mm; lateral, −5 mm. The dura at each burr hole
was pierced sharply. Then, 600 μL of blood was aspirated
from the tail artery; the last 125 μL of nonheparinized blood
was aspirated into a syringe equipped with a 22-mm-long
blunt, tapered-tip needle (Hamilton custom tapered syringe,
7732-01; Hamilton Co., Reno, NV, USA). The syringe was
mounted in the stereotaxic apparatus and the tip coordinates
were registered. Beginning at the burr hole on the right side,
the needle was advanced to the z-coordinate of −7.0, then was
advanced very slowly until the curvature of the posterior
aspect of the middle fossa was reached, as indicated by the
needle shifting slightly anteriorly [at the z-coordinate (mean±
SD), −8.3±0.4 mm; range, −7.3 to −9.2 mm]. Use of a blunt,
tapered-tip needle prevented the dura and bone from being
pierced, allowing reliable access to the subarachnoid space.
Without adjusting the depth, 50 μL of blood was injected over
5 min, after which 5 min was allowed to elapse before slowly
withdrawing the needle. The procedure was repeated on the
left side.
Treatment
In rats that would be administered drug, IV access to the
external jugular vein was obtained under microscopic visu-
alization. A mini-osmotic pump (1.0 μL/h; Azlet 2001,
Durect Corporation, Cupertino, CA, USA) fitted with a rat
jugular vein catheter (#0007710, Alzet, Durect Corporation,
Cupertino, CA, USA) was implanted. The catheter was
filled sequentially with 11 μL of NS, 1 μL of air, and the
remainder with the solution to be administered; the first 12
μL in the catheter provided a 12-h delay in the start of drug
administration [75]. The pumps were filled either with NS or
with heparin sodium (5,000 USP U/ml; APP Pharmaceuticals,
LLC, Schaumburg, IL, USA) in NS (1ml of heparin stock plus
0.43 ml NS) that delivered 10 U/kg/h. Therapeutic anticoagu-
lation in the rat requires constant infusion of 75 U/kg/h of
heparin [42].
Histochemistry
After transcardiac perfusion/fixation with 10 % neutral buff-
ered formalin, the brains were cryoprotected with 30 %
sucrose. For routine histology, cryosections (10 μm) were
stained with H&E and examined using light microscopy.
To assess myelin, cryosections (10 μm) were stained with
Black Gold II according to manufacturer’s protocol (Black
Gold II Myelin Staining Kit, AG105, Millipore, Teme-
cula, CA, USA). Briefly, slides were first rehydrated
and incubated in prewarmed 0.3 % Black Gold II solu-
tion at 60°C for 15 min. Sections were then rinsed
twice, and then incubated in 1 % sodium thiosulfate
solution for 3 min at 60°C. After several rinses with
Milli-Q water, the sections were counterstained with
cresyl violet to visualize nuclei, were coverslipped, and
were examined using light microscopy.
To identify degenerating neurons and white matter tracts,
cryosections (10 μm) were labeled with Fluoro-Jade C
histofluorescent stain [70] according to the manufacturer’s
protocol (Histo-Chem, Jefferson, AR, USA). Sections were
coverslipped with nonpolar mounting medium (Cytoseal
XYL, Richard-Allan Scientific, Kalamazoo, MI, USA) and
were examined with an epifluorescence microscope (Nikon
Eclipse 90i) under a fluorescein isothiocyanate filter, with
care being taken to limit the time of exposure in order to
reduce photobleaching.
Immunohistochemistry
Cryosections (10 μm) were first blocked (5 % goat serum,
Sigma+0.2 % Triton X-100 for 1 h at room temperature)
and then incubated overnight at 4°C with the following
primary antibodies: rabbit anti-ionized calcium-binding
adapter molecule 1 (Iba1) (1:1,000; Wako Chemicals,
Richmond, VA, USA); mouse anti-ED-1 (1:200;
MAB1435; Millipore, Temecula, CA, USA); rabbit anti-
myeloperoxidase (1:200; A0398; Dako, Carpinteria, CA,
USA); rabbit antinuclear factor-kappa B (p65) (1:200;
sc-372; Santa Cruz Biotechnology, Santa Cruz, CA,
USA); rabbit anticleaved caspase-3 (1:200; Asp175; Cell
Signaling Technologies, Beverly, MA, USA); mouse
antiglial fibrillary acidic protein (GFAP) (1:500; CY3
conjugated; C-9205; Sigma, St. Louis, MO, USA); goat
antitumor necrosis factor-alpha (TNFα) (1:100; N-19,
#SC-1350; Santa Cruz Biotechnology, Santa Cruz, CA,
USA); rabbit anti-interleukin-1beta (IL-1β; #AB9787;Abcam,
Cambridge MA, USA).
After several rinses in phosphate-buffered saline, the
slides were incubated for 1 h with fluorescent-labeled
species-appropriate secondary antibodies (1:500; Alexa
Flour 488 and Alexa Flour 555; Invitrogen, Molecular
Probes, Eugene, OR, USA) at room temperature. Omission
of primary antibody was used as a negative control. The
sections were coverslipped with polar mounting medium
containing antifade reagent and 4′,6-diamidino-2-phenylin-
dole (DAPI; Invitrogen, Eugene, OR, USA) and were ex-
amined using epifluorescence microscopy (Nikon Eclipse
90i; Nikon Instruments Inc., Melville, NY, USA). In some
cases, for the sake of clarity of presentation, epifluorescence
images are presented in the figures as “inverse” images,
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wherein the brightness value of each pixel is converted to
the inverse value on a 256-step scale.
Quantitative Immunohistochemistry
Quantifications comparing the effect of vehicle vs. heparin
were made using the right side of the brain. Unbiased
measurements of specific labeling within regions of interest
(ROI) were obtained using NIS-Elements AR software
(Nikon Instruments, Melville, NY, USA) from sections
immunolabeled in a single batch, as previously described
[26, 60]. All ROI images for a given signal were captured
using uniform parameters of magnification, area, exposure,
and gain. The following ROIs were defined: (1) for MPO,
ED1, p65, TNFα, and IL-1β in the entorhinal cortex, a
rectangular ROI, 1×1 mm, that was positioned on the pial
surface; (2) for Iba1 in the hippocampus, a rectangular ROI
that was positioned on the perforant pathway (see Fig. 6);
(3) for Black Gold II in the hippocampus, a rectangular ROI
that was positioned in the region between the perforant
pathway and the dentate gyrus (see Fig. 7); (4) for Fluoro-
Jade C in the hippocampus, a rectangular ROI, 450×
360 μm, that was positioned at the hilus of the dentate
gyrus. Segmentation analysis was performed by computing
a histogram of pixel intensity for a particular ROI. Specific
labeling was defined as pixels with signal intensity greater
than two times that of background. For MPO, ED1, and p65,
we performed object counts for specific labeling, which for
MPO and ED1 corresponded to the number of cells. For
Iba1 and Black Gold II, the area occupied by pixels with
specific labeling was used to determine the percent area with
specific labeling (%ROI). For Fluoro-Jade C, we counted
the number of neurons within the ROI.
Statistical Analysis
Calculations were performed with OriginPro8 (OriginLab
Corp., Northampton, MA, USA). Statistical comparisons
were made using Student’s t test or a one-way analysis of
variance with Fisher’s post hoc comparison, as appropriate.
Results
SAH Involving the Entorhinal Cortex
Using the methods described, we were able to take advan-
tage of the natural curvature of the calvarium to reproduc-
ibly locate the subarachnoid space over the posterolateral
temporal lobe and to produce a SAH that accumulated over
the entorhinal cortex (Fig. 1a). The technique used, includ-
ing the amount of blood and its slow injection, did not result
in an ischemic injury to the region (Fig. 1b). Blood was
largely confined to the subarachnoid space (Fig. 1c–e).
Vasoconstriction or vasospasm of vessels in the subarach-
noid space was not observed (Fig. 1e). This model was
associated with near-zero mortality, with the rare deaths
being attributable to anesthesia or surgery.
Neurodegeneration in the Entorhinal Cortex
At 48 h after SAH, the adjacent cortex and white matter,
including numerous neuron-like pyramidal cells, stained
heavily with Fluoro-Jade C, as did the ipsilateral but not
the contralateral perforant pathway (Fig. 2a, c, d). Saline
injection did not result in staining with Fluor-Jade C above
background levels (Fig. 2b). The cortical region that stained
with Fluoro-Jade C showed downregulation of GFAP, but
the surrounding tissues showed reactive astrocytosis
(Fig. 2c, e). Compared to the control, the cortical region
that stained with Fluoro-Jade C was depleted of NeuN-
positive cells (Fig. 2f, g).
Fig. 1 SAH involving the entorhinal cortex. a Image of the base of the
brain showing SAH involving the entorhinal cortex bilaterally; dotted
line location of parasagittal sections. b Parasagittal section of the brain
stained with TTC showing the absence of infarction in the region of
SAH (arrow). c–e Parasagittal sections of the brain in the region of
SAH stained with H&E showing that the hemorrhage is localized
largely in the subarachnoid space and that subarachnoid vessels show
no evidence of vasoconstriction or vasospasm. All tissues were har-
vested 48 h after injury; the images shown are representative of find-
ings in 28 rats (a), 3 rats (b), or 5 rats (c–e)
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Neuroinflammation in the Entorhinal Cortex
At 48 h after SAH, adjacent subpial tissues showed upregu-
lation of the p65 subunit of nuclear factor-kappa B (NF-κB)
in cells and microvessels, with p65 expression tapering off
to normal within a few hundred micrometers (Fig. 3a, b).
The subpial tissues were infiltrated with neutrophils and
ED1-positive cells, consistent with macrophages and acti-
vated, phagocytic microglia (Fig. 3c). Immunolabeling for
Iba1, which identifies all microglia regardless of their acti-
vation state, showed a gradient, from the pial edge to deeper,
of cells with a rounded, activated morphology subpially that
transitioned into a less activated morphology further away
(Fig. 3d).
Effect of Heparin on Neuroinflammation in the Entorhinal
Cortex
We examined the effect of heparin on counts of neutrophils,
ED1-positive cells, and p65 upregulation in subpial tissues
of the entorhinal cortex (Fig. 4). Immunolabeling for MPO
showed that the subpial distribution of neutrophils appeared
similar (Fig. 4a, b) and that counts of neutrophils were
reduced, but not statistically different (Fig. 4e) in the two
groups. Immunolabeling for ED1 showed that the “front” of
ED1-positive cells appeared to extend less deeply (Fig. 4c,
d) and that counts of ED1-positive cells were significantly
reduced by heparin (Fig. 4e). Immunolabeling for p65
showed that upregulation of p65 was significantly reduced
by heparin (Fig. 4e).
We also examined the effect of heparin on the expression
of TNFα and IL-1β in subpial tissues of the entorhinal
cortex (Fig. 5). Immunolabeling for TNFα showed that the
“front” of TNFα was less prominent and extended less
deeply with heparin (Fig. 5a, b, e). Similarly, the expression
of IL-1β as well as the count of IL-1β-positive cells were
significantly reduced by heparin (Fig. 5c–e).
Effect of Heparin on Neuroinflammation
in the Hippocampus
Immunolabeling for MPO, ED1, and p65 showed that none
of these markers of inflammation were present in the hip-
pocampus (not shown). Nevertheless, there was evidence of
microglial activation, based on immunolabeling for Iba1
(Fig. 6), which identifies microglia regardless of activation
state. In contrast to the Iba1-positive, ED1-positive, large,
rounded, phagocytic microglia without processes observed
subpially in the entorhinal cortex, microglial activation in
the hippocampus was more muted. In the hippocampus of
vehicle-treated rats, Iba1-positive cells were numerous
(Fig. 6a); also, the cells were plump but not rounded and
the processes were often enlarged (Fig. 6c). In heparin-
Fig. 2 Cortical neurodegeneration following SAH. a Coronal section
from a rat with unilateral injection of 50 μL of autologous blood into
the subarachnoid space of the entorhinal cortex, stained with Fluoro-
Jade C (FJ); note the bright staining above the background in the
cortex and underlying white matter near the hemorrhage, along with
the bright staining of the perforant pathway ipsilateral (arrows) but not
contralateral to the hemorrhage; asterisk denotes hemorrhage. b–e
Parasagittal sections of rat brains in the region of injection of saline
(b) or blood (c–e), stained with Fluoro-Jade C (b–d) and immunola-
beled for GFAP (b, c, e) showing degeneration involving neuron-like
cells in the cortex beneath the SAH (c, d), but not with saline (b) and
reactive astrocytes surrounding the region that stains for Fluoro-Jade C
(c, e). f, g Coronal sections from a rat with unilateral injection of 50 μL
of autologous blood into the subarachnoid space of the entorhinal
cortex, immunolabeled for NeuN, showing the entorhinal cortex ipsi-
lateral (f) and contralateral (g) to the hemorrhage; note the loss of
ipsilateral entorhinal cortex neurons (ECNs) throughout the region,
except laterally, and the preservation of neurons in the ipsilateral
CA1 region and in all regions contralaterally (g); asterisk denotes
hemorrhage; same rat as in a. All tissues were harvested 48 h after
injury; the images shown are representative of findings in five rats (b–e)
or three rats (a, f, g)
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treated rats, Iba1-positive cells were less prominent (Fig. 6b),
the cell bodies were small, and the processes were finer
(Fig. 6d). Upregulation of Iba1 was significantly reduced by
heparin (Fig. 6e).
Myelin is highly susceptible to injury by oxidative stress
[76].We evaluated myelin preservation by stainingwith Black
Gold II. Myelin was visibly deficient in the perforant pathway
and in the dentate gyrus of vehicle-treated rats (Fig. 7a, c),
consistent with the previous observation of Fluro-Jade C
staining of the perforant pathway (Fig. 2a). By contrast, my-
elin appeared to be better preserved in the perforant pathway
and dentate gyrus of heparin-treated rats (Fig. 7b, d). Quanti-
fication of myelin in the region between the perforant pathway
and the dentate gyrus showed that myelin was significantly
better preserved with heparin (Fig. 7e).
In vehicle-treated rats, many granule cells of the dentate
gyrus exhibited pyknotic nuclei that immunolabeled for
cleaved caspase-3 (Fig. 8a) and that stained with Fluoro-
Fig. 4 Heparin reduces cortical neuroinflammation (microglial activa-
tion) following SAH. a–d Parasagittal sections immunolabeled for
myeloperoxidase (MPO) to identify neutrophils (a, b) or ED1 to
identify macrophages and phagocytic, activated microglia (c, d) from
rats treated with vehicle (a, c) or heparin (b, d); the advancing front of
neutrophils, depicted by arrows (a, b), was similar without and with
heparin; the advancing front of ED1-positive macrophages and micro-
glia, depicted by arrows (c, d), was reduced by heparin; asterisk
denotes the location of the SAH; the images shown are “inverse”
epifluorescence images. e Bar graphs showing counts of MPO-
positive cells, ED1-positive cells, and upregulation of p65 in rats
treated with vehicle (Veh) or heparin (Hep); *P<0.05; **P<0.01; five
rats per group
Fig. 3 Cortical neuroinflammation following SAH. a, b Parasagittal
section immunolabeled for NF-κB (p65), shown at low (a) and high (b)
magnification, demonstrating (1) prominent expression of p65 subpially
near the hemorrhage (asterisk) that tapers off with distance (a); (2)
involvement of individual cells as well as elongated structures consistent
with microvessels (arrows) (b); the image shown in a is an “inverse”
epifluorescence image. c Parasagittal section immunolabeled for myelo-
peroxidase (MPO) to identify neutrophils (note also the polymorphic
nuclei) and ED1 to identify macrophages and phagocytic, activated
microglia, showing tissue infiltration beneath the pia (dotted line). d
Parasagittal section immunolabeled for Iba1, to identify microglia, show-
ing (1) large rounded cells (a and inset a) beneath the pia (dotted line),
consistent with the phagocytic, activated microglia labeled with ED1 in c;
(2) small cells with complex processes further away from the hemorrhage
(b and inset b). All tissues were harvested 48 h after injury; the images
shown are representative of findings in five rats
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Jade C (Fig. 8c). All Fluoro-Jade C-positive cells had
pyknotic nuclei (Fig. 8e), also consistent with apoptosis.
These findings were less prominent in rats treated with
heparin (Fig. 8b, d). Quantification showed that Fluoro-
Jade C-positive cells were significantly reduced with hepa-
rin (Fig. 8f).
Discussion
We studied neuroinflammation in a model of SAH that
involved the eloquent cortex and that was devoid of a global
insult. To characterize microglial activation, we used two
antibodies that convey complementary information. The
ED1 antibody is a macrophage marker that recognizes an
intracytoplasmic, lysosomal antigen whose expression
increases during phagocytic activity in monocytes and other
tissue macrophages, including microglia [3, 15, 28]. The
Iba1 antibody is a marker directed against a microglia-
specific antigen that identifies nonactivated (resting), as well
as activated but nonphagocytic microglia that are ED1-
negative [28]. Using these and other antibodies, we found
a neuroinflammatory response in the entorhinal cortex adja-
cent to the hemorrhage that was robust, with invasion of
neutrophils, ED1-positive cells, phagocytic microglia, and
macrophages, and prominent labeling for NF-κB, TNFα,
and IL-1β [16, 77]. This robust neuroinflammatory re-
sponse was associated with significant neurodegeneration,
marked by Fluoro-Jade C staining and loss of NeuN label-
ing. The robust inflammatory response in the entorhinal
cortex was very different from the muted inflammatory
response observed remotely in the hippocampus, where
there was no labeling for MPO, ED1, or NF-κB and where
the principal evidence for neuroinflammation was the ap-
pearance of Iba1-positive microglia that exhibited an
Fig. 5 Heparin reduces cortical neuroinflammation (TNFα and IL-1β)
following SAH. a–d Parasagittal sections immunolabeled for TNFα (a,
b) or IL-1β (c, d) from rats treated with vehicle (a, c) or heparin (b, d);
the advancing front of TNFα, depicted by arrows (a, b), was reduced
by heparin; asterisk denotes the location of the SAH; the images shown
in a and b are “inverse” epifluorescence images. e Bar graphs showing
the percentage of the ROI immunolabeled for TNFα or IL-1β, as well
as the number of cells immunolabeled for IL-1β, as indicated, in rats
treated with vehicle (Veh) or heparin (Hep); *P<0.05; **P<0.01; five
rats per group
Fig. 6 Heparin reduces hippocampal neuroinflammation following
SAH. a–d Parasagittal sections immunolabeled for Iba1, shown at
low (a, b) and high (c, d) magnification, from rats treated with vehicle
(a, c) or heparin (b, d); note the “plump” morphology of microglia in
the controls (c), which is absent with heparin (d); CA1 cornu ammonis
region 1, PP perforant pathway, DG dentate gurus; the ROI analyzed
are depicted by rectangles; the images shown in a and b are “inverse”
epifluorescence images. e Bar graph quantifying Iba1 in the ROI in rats
treated with vehicle (Veh) or heparin (Hep); *P<0.05; five rats per group
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activated morphology. Overall, our findings on neuroin-
flammation associated with SAH are consistent with previ-
ous reports [2, 11, 17, 24, 29, 52, 61, 64, 72, 73, 77, 78, 84].
What may be an importance difference, however, is that, in
many of the previous reports, either the model used (endo-
vascular puncture) or the amount of blood injected (200–
500 μL) could potentially have been associated with a
widespread or global ischemic insult, whereas in our experi-
ments, the manner of injection and the amount of blood
injected (50 μL on each side) were highly unlikely to
produce an ischemic injury, as confirmed by the lack of
vasoconstriction or vasospasm of vessels in the subarachnoid
space and by uniformly positive tissue staining with TTC.
The major finding of the present study is that delayed IV
infusion of heparin, at a dose that does not produce thera-
peutic anticoagulation, significantly reduced neuroinflam-
mation associated with SAH, both the proximate effect in
the entorhinal cortex, as well as the remote effect in the
hippocampus. Heparin is a pleiotropic drug that has long
been recognized to have broad anti-inflammatory and im-
munomodulatory activities that are independent of its anti-
coagulant effect [18, 44, 45, 65, 80, 86]. More than 100
heparin-binding proteins are known [86], with the growing
list including numerous plasma proteins, proteins released
from platelets, cytokines, chemokines, and other small, bi-
ologically active molecules, as well as endothelial cells
themselves [14, 25, 32, 36, 51, 65]. The anti-inflammatory
effects of heparin are due to a number of interactions: (1)
inhibition of complement activation [23, 83]; (2) binding to
the leukocyte adhesion molecules, P- and L-selectin [65,
81]; (3) inhibition of the cationic neutrophil proteases, hu-
man leukocyte elastase, and cathepsin G [23, 65]; (4) dis-
ruption of Mac-1 (CD11b/CD18)-mediated leukocyte
adhesion to the receptor for advanced glycation end
Fig. 7 Heparin reduces demyelination of the perforant pathway fol-
lowing SAH. a–d Parasagittal sections stained with Black Gold II,
shown at low (a, b) and high (c, d) magnification, from rats treated
with vehicle (a, c) or heparin (b, d); PP perforant pathway, DG dentate
gyrus; the ROI analyzed is depicted by the rectangle. e Bar graph
quantifying Black Gold II-stained myelin in the ROI in rats treated
with vehicle (Veh) or heparin (Hep); **P<0.01; five rats per group
Fig. 8 Heparin reduces apoptosis of granule cells of the dentate gyrus
following SAH. a–d Parasagittal sections of the dentate gyrus immu-
nolabeled for cleaved caspase-3 (a, b) or stained with Fluoro-Jade C (c,
d) from rats treated with vehicle (a, c) or heparin (b, d). e Granule cells
of the dentate gyrus from a vehicle-treated rat, double stained with
DAPI and with Fluoro-Jade C (FJ), as indicated, showing pyknotic
nuclei of apoptotic cells (arrows); superimposed images are also
shown. f Bar graph quantifying Fluoro-Jade C-stained granule cells
in the dentate gyrus of naïve (uninjured) rats (CTR), rats with bilateral
SAH treated with vehicle (Veh) or heparin (Hep); **P<0.01; three
naïve rats and eight rats per group with SAH
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products (RAGE) [65]; (5) inhibition of RAGE ligation by
its many proinflammatory ligands, including the advanced
glycation end product, carboxymethyl lysine–bovine serum
albumin, the nuclear protein, high mobility group box
protein-1, and S100 calgranulins [46, 47, 53, 65, 67]; (6)
inhibition of the nuclear translocation of NF-κB and a
decrease in NF-κB–DNA binding in the endothelium [79].
A recent comprehensive review showed that heparin
exhibits a broad diversity of biological effects, many of
which can be directly linked to pathophysiological mecha-
nisms that have been implicated in SAH-induced DNDs
[74]. Among its wide-ranging effects, heparin (1) complexes
with free hemoglobin, including oxyhemoglobin [1]; (2)
blocks the activity of free radicals including reactive oxygen
species [20]; (3) antagonizes endothelin-mediated vasocon-
striction [12, 41, 85]; (4) accelerates antithrombin-III-
mediated degradation of thrombin [57] which is implicated
in protracted vasoconstriction [35]; (5) binds to several
growth factors, thereby imparting antimitogenic [33, 34,
39] and antifibrotic [66] effects; and as reviewed above,
(6) exerts potent multitargeted anti-inflammatory effects.
The efficacy reported here for heparin against neuroinflam-
mation, combined with the fact that the dose we used was
less than that required for therapeutic anticoagulation [4,
42], suggests that heparin may be a safe prophylactic agent
for reducing DNDs associated with SAH.
Despite the absence of a global insult, we identified
extensive cell degeneration and cell death in this model,
especially in the entorhinal cortex and white matter near
the SAH. Hippocampal and cortical cell death and neuronal
apoptosis have been previously documented, both in models
of SAH and in humans with SAH [7, 54], but the trigger for
apoptosis is not always known. With the endovascular per-
foration models, cell death has been attributed to a global
insult, e.g., an elevation of the intracranial pressure resulting
in global ischemia/hypoxia [19, 58, 59, 63]. However, sev-
eral studies have shown that SAH produced by cautious
blood injection can be also associated with neuronal apo-
ptosis, independent of increased intracranial pressure [49,
50, 68, 82]. In the absence of a global ischemic insult, the
actual trigger for cell death is often uncertain [7].
Given the absence of a global insult, the absence of direct
mechanical or hemorrhagic injury to the hippocampus, and
the muted inflammatory response in the hippocampus, we
were initially surprised to find apoptosis of granule cells of
the dentate gyrus. Apoptosis of granule cells was character-
ized by pyknotic nuclei that stained with Fluoro-Jade and
showed cleaved caspase-3. The fact that we were injuring
the entorhinal cortex gave rise to the possibility that, if not
attributable to a global insult or to direct injury, apoptosis
might be due instead to a transsynaptic process. Transsy-
naptic degeneration and transsynaptic apoptosis have been
well documented under a variety of conditions in many
brain regions following deafferentation, including the sys-
tem of entorhinal cortex–perforant pathway–dentate gyrus
that we studied here [27, 40, 71]. Our findings of degener-
ation/demyelination of the perforant pathway, as indicated
by Fluoro-Jade C staining [69], and diminished labeling
with Black Gold II are consistent with deafferentation of
dentate gyrus cells secondary to the robust inflammatory
response in the entorhinal cortex. Injury to the perforant
pathway that causes deafferentation of granule cells renders
these cells susceptible to excitotoxic injury and apoptotic
death [40]. Moreover, transsynaptic apoptosis is worsened
by neuroinflammation [13], as we observed here. Impor-
tantly, demyelination and transsynaptic apoptosis in our
model were largely blocked by delayed IV infusion of
low-dose heparin.
To our knowledge, transsynaptic apoptosis has not been
previously identified in SAH. The potential implications of
transsynaptic apoptosis in SAH may be large, especially if
SAH involves the eloquent cortex. Distinct from generally
recognized triggers of apoptosis, such as direct tissue trau-
ma, ischemia, inflammation, etc., transsynaptic apoptosis
involves the spread of cell death beyond the boundaries of
the immediate injury to involve otherwise uninjured neurons
that are an axon’s length away. This phenomenon may help
to explain the prevalence of cognitive and neuropsycholog-
ical deficits that commonly afflict humans with “mild-to-
moderate” SAH who do not suffer a global insult [6, 10].
In summary, our findings here support previous work
showing a robust neuroinflammatory response in the cortex
underlying SAH which can lead to nearby tissue damage
and cell death, as well as remote transsynaptic apoptosis.
Our studies also show that delayed IV infusion of low-dose
heparin exerts a powerful anti-inflammatory effect that less-
ens tissue injury and reduces transsynaptic apoptosis.
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